Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients, - 02/02/23
, Sameer Prakash a, c, Antonio J. Sanchez aHighlights |
• | Pi*MZ variant is an independent predictor of development of hepatic decompensation events in patients with NAFLD. |
• | Clinicians should consider testing for alpha-1-antitrypsin phenotype in NAFLD patients. |
• | Patients with NAFLD & Pi*MZ should be counseled about increased risk of hepatic decompensation and offered aggressive interventions . |
Abstract |
Aims |
Heterozygous alpha-1-antitrypsin (A1AT) Pi*MZ variant has been shown to increase the risk of developing liver cirrhosis in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to determine the association between heterozygous Pi*MZ and Pi*MS variants and development of hepatic decompensation events in NAFLD patients.
Methods |
We included patients with NAFLD who also had A1AT genotyping performed from 2005 to 2020. We recorded demographic and clinical variables, and data on hepatic events (ascites, hepatic encephalopathy, esophageal variceal bleed, or hepatocellular carcinoma), if any. We performed binary logistic regression analysis to assess the association between A1AT variants and hepatic events, and calculated Odds ratio (OR) with their 95% confidence intervals (Cl).
Results |
We included 1532 patients with NAFLD, of which 1249 patients had Pi*MM, 121 had Pi*MS, and 162 had Pi*MZ. Of the 1532 patients, hepatic events developed in 521 (34%) patients. The percentage of patients with Pi*MZ variant was significantly higher in patients with hepatic events as compared to patients without hepatic events (18.7 % vs 8.1%, p<0.0001). Pi*MZ variant was noted to significantly increase the odds of developing hepatic events in NAFLD patients, unadjusted OR: 1.82 (1.3–2.5, p<0.001), adjusted OR (for age, sex, body mass index, and diabetes mellitus) 1.76 (1.2–2.5, p = 0.002). Pi*MS variant did not increase the odds of hepatic events in NAFLD patients, OR: 0.92 (0.6–1.4, p = 0.70).
Conclusion |
Patients with NAFLD and A1AT Pi*MZ variant are at increased risk for developing hepatic decompensation. NAFLD patients should be offered A1AT genotyping for risk stratification, counseling, and multidisciplinary intervention for NAFLD.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Keywords : Hepatic decompensation, Alpha1-antitrypsin deficiency, Cirrhosis, Encephalopathy, Variceal bleeding, Ascites, Hepatocellular carcinoma, Heterozygous, genotyping, NAFLD
Abbreviations : A1AT, ALP, ALT, AST, BMI, CI, GGT, HCC, NAFLD, NASH, OR, WBC
Plan
| ✰ | This study was performed at the University of Iowa with grant support from the University of Iowa Clinical Research Grant. |
| ✰✰ | Part of the study was presented as an oral presentation at the Scientific Session at the AASLD Meeting 2021. |
Vol 47 - N° 2
Article 102066- février 2023 Retour au numéro
Article précédent
- Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?
- Menglei Wang, Jingyang Su, Jinhua Lu, Ze Yang, Jue Wang, Yazhen Zhong, Tianni Zeng, Kezhan Shen, Shengyou Lin
- Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey
- Manon Allaire, Sylvain Manfredi, Léa Lerosey, Nathalie Ganne-Carrié, Dominique Thabut
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?